Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion plus Non-Small-Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Gainor, J. F. [1 ]
Curigliano, G. [2 ]
Kim, D. -W. [3 ]
Lee, D. H. [4 ]
Besse, B. [5 ]
Baik, C. S. [6 ]
Doebele, R. C. [7 ]
Cassier, P. [8 ]
Lopes, G. [9 ]
Tan, D. S. -W. [10 ]
Garralda, E. [11 ]
Paz-Ares, L. [12 ]
Cho, B. C. [13 ]
Gadgeel, S. M. [14 ]
Thomas, M. [15 ]
Liu, S. V. [16 ]
Clifford, C. [17 ]
Zhang, H. [17 ]
Turner, C. D. [17 ]
Subbiah, V. [18 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[3] Seoul Natl Univ Hosp, Seoul, South Korea
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Gustave Roussy Univ Paris Sud, Villejuif, France
[6] Univ Washington, Sch Med, Main Hosp Seattle, Seattle, WA 98195 USA
[7] Univ Colorado, Canc Ctr, Aurora, CO USA
[8] Ctr Leon Berard, Lyon, France
[9] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[10] Natl Canc Ctr Singapore, Singapore, Singapore
[11] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[12] Hosp Univ 12 Octubre, Madrid, Spain
[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[14] Henry Ford Canc Inst, Detroit, MI USA
[15] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[16] Georgetown Univ, Washington, DC USA
[17] Blueprint Med Corp, Cambridge, MA USA
[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO01.38
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [1] Registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small-cell lung cancer (NSCLC)
    Thomas, M.
    Griesinger, F.
    Schuler, M.
    Gainor, J. F.
    Curigliano, G.
    Kim, D. -W.
    Lee, D. H.
    Besse, B.
    Baik, C. S.
    Doebele, R. C.
    Cassier, P.
    Lopes, G.
    Tan, D. S. -W.
    Garralda, E.
    Paz-Ares, L.
    Cho, Chul B.
    Gadgeel, S. M.
    Liu, S. V.
    Turner, C. D.
    Subbiah, V.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 141 - 142
  • [2] Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe Alexandre
    Lopes, Gilberto
    Tan, Daniel Shao-Weng
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen, V
    Clifford, Corinne
    Zhang, Hui
    Turner, Christopher D.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
    Hu, M.
    Subbiah, V.
    Wirth, L. J.
    Schuler, M.
    Mansfield, A. S.
    Brose, M. S.
    Curigliano, G.
    Leboulleux, S.
    Zhu, V. W.
    Keam, B.
    Matos, I.
    Lin, C-C.
    Adkins, D.
    Baik, C. S.
    Lopes, G.
    Godbert, Y.
    Sarker, D.
    Zhang, H.
    Turner, C.
    Taylor, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1084 - S1084
  • [4] Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
    Keam, B.
    Hu, M. I.
    Subbiah, V.
    Wirth, L.
    Schuler, M.
    Mansfield, A. S.
    Brose, M. S.
    Curigliano, G.
    Leboulleux, S.
    Zhu, V. W.
    Matos, I.
    Adkins, D.
    Baik, C. S.
    Lopes, G.
    Godbert, Y.
    Sarker, D.
    Zhang, H.
    Turner, C. D.
    Taylor, M. H.
    Lin, C-C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1413 - S1414
  • [5] Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Lee, Dae Ho
    Curigliano, Giuseppe
    Doebele, Robert Charles
    Kim, Dong-Wan
    Baik, Christina S.
    Tan, Daniel Shao-Weng
    Lopes, Gilberto
    Gadgeel, Shirish M.
    Cassier, Philippe Alexandre
    Taylor, Matthew H.
    Liu, Stephen V.
    Besse, Benjamin
    Thomas, Michael
    Zhu, Viola Weijia
    Zhang, Hui
    Clifford, Corinne
    Palmer, Michael
    Turner, Christopher D.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC)
    Besse, B.
    Griesinger, F.
    Curigliano, G.
    Thomas, M.
    Subbiah, V.
    Baik, C. S.
    Tan, D. S. W.
    Lee, D. H.
    Garralda, E.
    Kim, D-W.
    Van Der Wekken, A. J.
    Gainor, J.
    Paz-Ares, L.
    Liu, S. V.
    Bowles, D. W.
    Zalutskaya, A.
    Ruf, T.
    Rahman, A.
    Chen, G.
    Mazieres, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1083 - S1084
  • [7] Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)
    Lee, D. H.
    Subbiah, V.
    Gainor, J. F.
    Taylor, M. H.
    Zhu, V. W.
    Doebele, R. C.
    Lopes, G.
    Baik, C.
    Garralda, E.
    Gadgeel, S. M.
    Kim, D-W.
    Turner, C. D.
    Palmer, M.
    Miller, S.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
    Curigliano, Giuseppe
    Gainor, Justin F.
    Griesinger, Frank
    Thomas, Michael
    Subbiah, Vivek
    Baik, Christina S.
    Tan, Daniel Shao-Weng
    Lee, Dae Ho
    Misch, Daniel
    Garralda, Elena
    Kim, Dong-Wan
    Paz-Ares, Luis G.
    Mazieres, Julien
    Liu, Stephen V.
    Kalemkerian, Gregory Peter
    Houvras, Yariv
    Bowles, Daniel W.
    Mansfield, Aaron Scott
    Zalutskaya, Alena
    van der Wekken, Anthonie J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer
    Zhou, Q.
    Wu, Y.
    Chang, J.
    Wang, H.
    Fan, Y.
    Zhao, J.
    Wu, G.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Nian, W.
    Wang, K.
    Zheng, X.
    Qu, L.
    Yao, S.
    Shen, Z.
    Li, P.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S889 - S890
  • [10] Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
    Gainor, J.
    Curigliano, G.
    Doebele, R. C.
    Lin, J. J.
    Ou, S. -H.
    Miller, S.
    Turner, C. D.
    Subbiah, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S5 - S5
12345